|
Characteristic N (%)
|
2000-2002
|
2003-2005
|
2006-2008
|
2009-2011
|
Total
|
P*
|
|---|
|
Total
|
1866
|
1849
|
1843
|
1767
|
3141
| |
|
Female sex
|
598 (31.8)
|
601 (32.3)
|
544 (29.3)
|
514 (28.4)
|
932 (29.7)
|
0.03
|
|
Race
| | | | | | |
|
Black
|
1136 (61.0)
|
1088 (58.9)
|
1047 (57.0)
|
997 (56.4)
|
1862 (59.3)
| |
|
White
|
591 (31.7)
|
610 (33.0)
|
596 (32.3)
|
563 (31.9)
|
962 (30.6)
| |
|
Other
|
142 (7.5)
|
153 (8.2)
|
202 (10.9)
|
207 (11.7)
|
317 (10.1)
|
<0.01
|
|
MSM
|
566 (30.3)
|
623 (33.6)
|
640 (34.6)
|
516 (29.2)
|
889 (28.3)
|
<0.01
|
|
IDU
|
261 (14.0)
|
248 (13.4)
|
208 (11.2)
|
152 (8.6)
|
340 (10.8)
|
<0.01
|
|
Age (years)†
|
40 (34–46)
|
42 (36–49)
|
44 (37–51)
|
46 (38–52)
|
43 (36–50)
|
<0.01
|
|
CD4 cell count (cells/mm3) †
|
376 (181–602)
|
403 (218–621)
|
440 (251–657)
|
519 (335–737)
|
440 (244–660)
|
<0.01
|
|
HIV RNA (log10 copies/ml) †
|
2.92 (2.30-4.47)
|
2.73 (BLD-4.45)
|
2.05 (BLD-4.05)
|
BLD (BLD-2.58)
|
2.37 (BLD-4.11)
|
<0.01
|
|
ART experience (person-years after ART exposure)‡
|
3322 (81.6)
|
3505 (83.7)
|
3680 (83.8)
|
3871 (88.0)
|
14378 (84.3)
|
<0.01
|
- *P-values from Chi-squared test for categorical and binary characteristics, and Kruskal-Willis test for continuous characteristics. Undetectable HIV RNA results were assigned a value of half the limit of detection for the purposes of assessing trends across time.
- †Median (Interquartile Range) presented for continuous characteristics.
- ‡The number of years of follow-up within the time interval contributed by ART-experienced patients and the percentage of all follow-up within the time interval that was contributed be ART-experienced patients.
- BLD: below limit of detection (<50 copies/mL); ART: antiretroviral therapy; MSM: men who have sex with men; IDU: injection drug user.
